The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Cancer vaccines: Building a bridge over troubled waters
Open accessAbstract
Cancer vaccines aim to direct the immune system to eradicate cancer cells. We review the essential immunologic concepts underpinning natural immunity, and highlight the multiple unique challenges faced by vaccines targeting cancer. Recent technological advances in mass spectrometry, neoantigen prediction, genetically and pharmacologically engineered mouse models, and single cell ‘omics have revealed new biology which can help to bridge this divide. We particularly focus on translationally relevant aspects, such as antigen selection and delivery and monitoring human post-vaccination responses, and encourage more aggressive exploration of novel approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Self-citationDendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors
Villani, A.-C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J., Griesbeck, M., Butler, A., Zheng, S., Lazo, S., et al. (2017) · Science · doi:10.1126/science.aah4573 · Cited by 2,413
Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361
Toll-like Receptors and the Control of Immunity
Fitzgerald, K. A., & Kagan, J. C. (2020) · Cell · doi:10.1016/j.cell.2020.02.041 · Cited by 2,168
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Myeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,767
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Signalling through C-type lectin receptors: shaping immune responses
Geijtenbeek, T. B. H., & Gringhuis, S. I. (2009) · Nature Reviews Immunology · doi:10.1038/nri2569 · Cited by 1,379
Human T cell development, localization, and function throughout life
Kumar, B. V., Connors, T. J., & Farber, D. L. (2018) · Immunity · doi:10.1016/j.immuni.2018.01.007 · Cited by 1,257
The ins and outs of MHC class II-mediated antigen processing and presentation
Roche, P. A., & Furuta, K. (2015) · Nature reviews. Immunology · doi:10.1038/nri3818 · Cited by 1,207
Tertiary lymphoid structures in cancer
Schumacher, T. N., & Thommen, D. S. (2022) · Science · doi:10.1126/science.abf9419 · Cited by 1,142
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
A conserved dendritic-cell regulatory program limits antitumour immunity
Maier, B., Leader, A. M., Chen, S. T., Tung, N., Chang, C., LeBerichel, J., Chudnovskiy, A., Maskey, S., Walker, L., Finnigan, J. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2134-y · Cited by 941
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 896
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846
Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738
Nielsen, M., Lundegaard, C., Blicher, T., Lamberth, K., Harndahl, M., Justesen, S., Røder, G., Peters, B., Sette, A., Lund, O., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000796 · Cited by 719
Bassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13404 · Cited by 693
Tan, W. C. C., Nerurkar, S. N., Cai, H. Y., Ng, H. H. M., Wu, D., Wee, Y. T. F., Lim, J. C. T., Yeong, J., & Lim, T. K. H. (2020) · Cancer Communications · doi:10.1002/cac2.12023 · Cited by 678
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
MDSC: Markers, development, states, and unaddressed complexity
Hegde, S., Leader, A. M., & Merad, M. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.004 · Cited by 669
Resolving genetic heterogeneity in cancer
Turajlic, S., Sottoriva, A., Graham, T., & Swanton, C. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0114-6 · Cited by 653
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J., Ruhland, M. K., Kersten, K., Abushawish, M. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., et al. (2020) · Nature · doi:10.1038/s41586-020-2611-3 · Cited by 611
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Wu, Y.-M., Cieślik, M., Lonigro, R. J., Vats, P., Reimers, M. A., Cao, X., Ning, Y., Wang, L., Kunju, L. P., de Sarkar, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.034 · Cited by 598
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
Oliveira, G., Stromhaug, K., Klaeger, S., Kula, T., Frederick, D. T., Le, P. M., Forman, J., Huang, T., Li, S., Zhang, W., et al. (2021) · Nature · doi:10.1038/s41586-021-03704-y · Cited by 558
Self-citationDeconstructing the Peptide-MHC Specificity of T Cell Recognition
Birnbaum, M. E., Mendoza, J. L., Sethi, D. K., Dong, S., Glanville, J., Dobbins, J., Özkan, E., Davis, M. M., Wucherpfennig, K. W., & Garcia, K. C. (2014) · Cell · doi:10.1016/j.cell.2014.03.047 · Cited by 556
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Caushi, J. X., Zhang, J., Ji, Z., Vaghasia, A., Zhang, B., Hsiue, E. H.-C., Mog, B. J., Hou, W., Justesen, S., Blosser, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03752-4 · Cited by 543
Huang, H., Wang, Z., Zhang, Y., Pradhan, R. N., Ganguly, D., Chandra, R., Murimwa, G., Wright, S., Gu, X., Maddipati, R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.011 · Cited by 542
Hu, Z., Leet, D. E., Allesøe, R. L., Oliveira, G., Li, S., Luoma, A. M., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01206-4 · Cited by 538
Self-citationCui, C., Wang, J., Fagerberg, E., Chen, P.-M., Connolly, K. A., Damo, M., Cheung, J. F., Mao, T., Askari, A. S., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.007 · Cited by 479
Liu, B., Hu, X., Feng, K., Gao, R., Xue, Z., Zhang, S., Zhang, Y., Corse, E., Hu, Y., Han, W., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00292-8 · Cited by 473
Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I. H., Schumacher, T. N. M., Melief, C. J. M., Offringa, R., & Toes, R. E. M. (1999) · Nature Medicine · doi:10.1038/10495 · Cited by 469
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi, J. L., Bobisse, S., Ophir, E., Tuyaerts, S., Roberti, A., Genolet, R., Baumgartner, P., Stevenson, B. J., Iseli, C., Dangaj, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao5931 · Cited by 450
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
Strønen, E., Toebes, M., Kelderman, S., van Buuren, M. M., Yang, W., van Rooij, N., Donia, M., Böschen, M.-L., Lund-Johansen, F., Olweus, J., et al. (2016) · Science · doi:10.1126/science.aaf2288 · Cited by 445
Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01188-3 · Cited by 436
Wicherska-Pawłowska, K., Wróbel, T., & Rybka, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413397 · Cited by 409
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382
Duong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., & Spranger, S. (2022) · Immunity · doi:10.1016/j.immuni.2021.10.020 · Cited by 372
An Introduction to B-Cell Epitope Mapping and In Silico Epitope Prediction
Potocnakova, L., Bhide, M., & Pulzova, L. B. (2016) · Journal of Immunology Research · doi:10.1155/2016/6760830 · Cited by 367
Lynn, G. M., Sedlik, C., Baharom, F., Zhu, Y., Ramirez-Valdez, R. A., Coble, V. L., Tobin, K., Nichols, S. R., Itzkowitz, Y., Zaidi, N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0390-x · Cited by 349
Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01211-7 · Cited by 336
Verma, V., Shrimali, R. K., Ahmad, S., Dai, W., Wang, H., Lu, S., Nandre, R., Gaur, P., Lopez, J., Sade-Feldman, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0441-y · Cited by 333
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
Cachot, A., Bilous, M., Liu, Y.-C., Li, X., Saillard, M., Cenerenti, M., Rockinger, G. A., Wyss, T., Guillaume, P., Schmidt, J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe3348 · Cited by 328
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers13061383 · Cited by 317
Sharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312
Pauthner, M., Havenar-Daughton, C., Sok, D., Nkolola, J. P., Bastidas, R., Boopathy, A. V., Carnathan, D. G., Chandrashekar, A., Cirelli, K. M., Cottrell, C. A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.05.007 · Cited by 305
The immunoproteasome and thymoproteasome: functions, evolution and human disease
Murata, S., Takahama, Y., Kasahara, M., & Tanaka, K. (2018) · Nature Immunology · doi:10.1038/s41590-018-0186-z · Cited by 304
Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer
Ouspenskaia, T., Law, T., Clauser, K. R., Klaeger, S., Sarkizova, S., Aguet, F., Li, B., Christian, E., Knisbacher, B. A., Le, P. M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01021-3 · Cited by 298
Self-citationThe EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292
Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., & Kast, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7855 · Cited by 292
B Cell Function in the Tumor Microenvironment
Downs-Canner, S. M., Meier, J., Vincent, B. G., & Serody, J. S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-015603 · Cited by 287
Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 255
The dawn of vaccines for cancer prevention
Finn, O. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.140 · Cited by 254
Controlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
Abdel-Hakeem, M. S., Manne, S., Beltra, J.-C., Stelekati, E., Chen, Z., Nzingha, K., Ali, M.-A., Johnson, J. L., Giles, J. R., Mathew, D., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00975-5 · Cited by 252
Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans
Yates, K. B., Tonnerre, P., Martin, G. E., Gerdemann, U., Al Abosy, R., Comstock, D. E., Weiss, S. A., Wolski, D., Tully, D. C., Chung, R. T., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00979-1 · Cited by 250
IgA transcytosis and antigen recognition govern ovarian cancer immunity
Biswas, S., Mandal, G., Payne, K. K., Anadon, C. M., Gatenbee, C. D., Chaurio, R. A., Costich, T. L., Moran, C., Harro, C. M., Rigolizzo, K. E., et al. (2021) · Nature · doi:10.1038/s41586-020-03144-0 · Cited by 248
Advances in spatial transcriptomic data analysis
Dries, R., Chen, J., del Rossi, N., Khan, M. M., Sistig, A., & Yuan, G.-C. (2021) · Genome Research · doi:10.1101/gr.275224.121 · Cited by 241
Abelin, J. G., Harjanto, D., Malloy, M., Suri, P., Colson, T., Goulding, S. P., Creech, A. L., Serrano, L. R., Nasir, G., Nasrullah, Y., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.012 · Cited by 240
Self-citationLegoux, F. P., Lim, J.-B., Cauley, A. W., Dikiy, S., Ertelt, J., Mariani, T. J., Sparwasser, T., Way, S. S., & Moon, J. J. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.011 · Cited by 238
Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer
Mehta, A. K., Kadel, S., Townsend, M. G., Oliwa, M., & Guerriero, J. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643771 · Cited by 231
The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues
Kok, L., Masopust, D., & Schumacher, T. N. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00590-3 · Cited by 230
Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 216
Hotz, C., Wagenaar, T. R., Gieseke, F., Bangari, D. S., Callahan, M., Cao, H., Diekmann, J., Diken, M., Grunwitz, C., Hebert, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc7804 · Cited by 215
Xin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Baharom, F., Ramirez-Valdez, R. A., Tobin, K. K. S., Yamane, H., Dutertre, C.-A., Khalilnezhad, A., Reynoso, G. V., Coble, V. L., Lynn, G. M., Mulè, M. P., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00810-3 · Cited by 202
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma
Oliveira, G., Stromhaug, K., Cieri, N., Iorgulescu, J. B., Klaeger, S., Wolff, J. O., Rachimi, S., Chea, V., Krause, K., Freeman, S. S., et al. (2022) · Nature · doi:10.1038/s41586-022-04682-5 · Cited by 196
Self-citationAntigen kinetics determines immune reactivity
Johansen, P., Storni, T., Rettig, L., Qiu, Z., Der-Sarkissian, A., Smith, K. A., Manolova, V., Lang, K. S., Senti, G., Müllhaupt, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706296105 · Cited by 184
The role of dendritic cells in cancer
Lee, Y. S., & Radford, K. J. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.07.006 · Cited by 171
Wei, J., Montalvo-Ortiz, W., Yu, L., Krasco, A., Ebstein, S., Cortez, C., Lowy, I., Murphy, A. J., Sleeman, M. A., & Skokos, D. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg0117 · Cited by 169
Danilova, L., Anagnostou, V., Caushi, J. X., Sidhom, J.-W., Guo, H., Chan, H. Y., Suri, P., Tam, A., Zhang, J., Asmar, M. E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0129 · Cited by 168
Antigen Dominance Hierarchies Shape TCF1+ Progenitor CD8 T Cell Phenotypes in Tumors
Burger, M. L., Cruz, A. M., Crossland, G. E., Gaglia, G., Ritch, C. C., Blatt, S. E., Bhutkar, A. J., Canner, D. A., Kienka, T., Tavana, S. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.020 · Cited by 167
Rosenblatt, J., Stone, R. M., Uhl, L., Neuberg, D., Joyce, R., Levine, J. D., Arnason, J., McMasters, M., Luptakova, K., Jain, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1298 · Cited by 164
Zhivaki, D., Borriello, F., Chow, O. A., Doran, B., Fleming, I., Theisen, D. J., Pallis, P., Shalek, A. K., Sokol, C. L., Zanoni, I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108381 · Cited by 163
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer
Kumar, A., Watkins, R., & Vilgelm, A. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690499 · Cited by 159
Richman, L. P., Vonderheide, R. H., & Rech, A. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.08.009 · Cited by 158
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
Morrison, A. H., Diamond, M. S., Hay, C., Byrne, K. T., & Vonderheide, R. H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918971117 · Cited by 155
Gupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 152
Kristensen, N. P., Heeke, C., Tvingsholm, S. A., Borch, A., Draghi, A., Crowther, M. D., Carri, I., Munk, K. K., Holm, J. S., Bjerregaard, A.-M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150535 · Cited by 150
Bhardwaj, N., Friedlander, P. A., Pavlick, A. C., Ernstoff, M. S., Gastman, B., Hanks, B. A., Curti, B. D., Albertini, M. R., Luke, J. J., Blazquez, A. B., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00143-y · Cited by 147
The lymph node at a glance – how spatial organization optimizes the immune response
Grant, S. M., Lou, M., Li, Y., Germain, R. N., & Radtke, A. J. (2020) · Journal of Cell Science · doi:10.1242/jcs.241828 · Cited by 140
Mysore, V., Culleré, X., Mears, J., Rosetti, F., Okubo, K., Liew, P. X., Zhang, F., Madera-Salcedo, I. K., Rosenbauer, F., Stone, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24591-x · Cited by 136
Surgery-mediated tumor-promoting effects on the immune microenvironment
Cheng, X., Zhang, H., Hamad, A., Huang, H., & Tsung, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.006 · Cited by 134
Williford, J., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 128
Pauken, K. E., Godec, J., Odorizzi, P. M., Brown, K. E., Yates, K. B., Ngiow, S. F., Burke, K. P., Maleri, S., Grande, S. M., Francisco, L. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107827 · Cited by 125
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue
Li, Z., Tuong, Z. K., Dean, I., Willis, C., Gaspal, F., Fiancette, R., Idris, S., Kennedy, B. C., Ferdinand, J. R., Peñalver, A., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20210749 · Cited by 124
Immunotherapy of Cancer by Targeting Regulatory T cells
Chen, B.-J., Zhao, J., Zhang, D., Zheng, A.-H., & Wu, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108469 · Cited by 122
Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy
Moorman, C. D., Sohn, S. J., & Phee, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657768 · Cited by 115
Korsholm, K. S., Hansen, J. U., Karlsen, K. K., Filskov, J., Mikkelsen, M., Lindenstrøm, T., Schmidt, S., Andersen, P. L., & Christensen, D. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.05.050 · Cited by 112
In Situ Vaccination for the Treatment of Cancer
Hammerich, L., Bhardwaj, N., Kohrt, H. E. K., & Brody, J. (2016) · Immunotherapy · doi:10.2217/imt.15.120 · Cited by 105
Kristensen, N. P., Heeke, C., Tvingsholm, S. A., Borch, A., Draghi, A., Crowther, M. D., Carri, I., Munk, K. K., Holm, J. S., Bjerregaard, A.-M., et al. (2021) · UCL Discovery (University College London) · Cited by 105
Fossum, E., Grødeland, G., Terhorst‐Molawi, D., Tveita, A. A., Vikse, E. L., Mjaaland, S., Henri, S., MALISSEN, B., & Bogen, B. (2014) · European Journal of Immunology · doi:10.1002/eji.201445080 · Cited by 103
Ren, Z., Zhang, A., Sun, Z., Liang, Y., Ye, J., Qiao, J., Li, B., & Fu, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153604 · Cited by 97
Han, P., Hanlon, D. J., Arshad, N., Lee, J. S., Tatsuno, K., Yurter, A., Robinson, E., Filler, R. B., Sobolev, O., Cote, C. M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz1580 · Cited by 95
Rakhra, K., Abraham, W. D., Wang, C., Moynihan, K. D., Li, N., Donahue, N. D., Baldeon, A. D., & Irvine, D. J. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd8003 · Cited by 89
Melo, M., Porter, E., Zhang, Y., Silva, M., Li, N., Dobosh, B., Liguori, A., Skog, P., Landais, E., Menis, S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.007 · Cited by 88
Zeng, B., Middelberg, A. P. J., Gemiarto, A. T., MacDonald, K. P. A., Baxter, A. G., Talekar, M., Moi, D., Tullett, K. M., Caminschi, I., Lahoud, M. H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96791 · Cited by 88
Wang, T.-Y., Liu, Q., Ren, Y., Alam, S. K., Wang, L., Zhu, Z., Hoeppner, L. H., Dehm, S. M., Cao, Q., & Yang, R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.028 · Cited by 81
Bullock, K. K., & Richmond, A. J. (2021) · Cancers · doi:10.3390/cancers13246293 · Cited by 79
Hernández, Á., Juanes‐Velasco, P., Landeira‐Viñuela, A., Bareke, H., Montalvillo, E., Góngora, R., & Fuentes, M. (2021) · Cancers · doi:10.3390/cancers13112821 · Cited by 76
Pan, Y., Liu, L., Tian, T., Zhao, J., Park, C. O., Lofftus, S. Y., Stingley, C. A., Yan, Y., Mei, S., Liu, X., et al. (2021) · npj Vaccines · doi:10.1038/s41541-020-00265-5 · Cited by 75
Harndahl, M. N., Rasmussen, M., Røder, G., & Buus, S. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.10.012 · Cited by 73
Lam, H., McNeil, L. K., Starobinets, H., DeVault, V. L., Cohen, R. B., Twardowski, P. W., Johnson, M. L., Gillison, M. L., Stein, M. N., Vaishampayan, U. N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0377 · Cited by 65
Plasmacytoid Dendritic Cells and Cancer Immunotherapy
Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2022) · Cells · doi:10.3390/cells11020222 · Cited by 64
Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
Nava, S., Lisini, D., Frigerio, S., & Bersano, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212339 · Cited by 62
Allavena, P., Anfray, C., Ummarino, A., & Torres, F. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1679 · Cited by 58
The ongoing saga of the mechanism(s) of MHC class I-restricted cross-presentation
Grotzke, J. E., Sengupta, D., Qiao, L., & Cresswell, P. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.03.015 · Cited by 54
The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice
Sultan, H., Kumai, T., Nagato, T., Wu, J., Salazar, A. Μ., & Celis, E. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-02294-5 · Cited by 54
Ren, Z., Zhang, A., Sun, Z., Liang, Y., Ye, J., Qiao, J., Li, B., & Fu, Y. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 54
Zou, W., Yaung, S. J., Fuhlbrück, F., Ballinger, M. D., Peters, E. J., Palma, J. F., Shames, D. S., Gandara, D. R., Jiang, Y., & Patil, N. S. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00057 · Cited by 52
Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination
Fagone, P., Shedlock, D. J., Bao, H., Kawalekar, O. U., Yan, J., Gupta, D., Morrow, M. P., Patel, A. R., Kobinger, G. P., Muthumani, K., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.59 · Cited by 51
Induced Pluripotent Stem Cell-Based Cancer Vaccines
Ouyang, X., Telli, M. L., & Wu, J. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01510 · Cited by 51
Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine
Belnoue, E., Mayol, J.-F., Carboni, S., Berardino-Besson, W. D., Dupuychaffray, E., Nelde, A., Stevanović, S., Santiago‐Raber, M., Walker, P. R., & Derouazi, M. (2019) · JCI Insight · doi:10.1172/jci.insight.127305 · Cited by 46
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope
Ebrahimi-Nik, H., Moussa, M. R., Englander, R. P., Singhaviranon, S., Michaux, J., Pak, H., Miyadera, H., Corwin, W. L., Keller, G. L. J., Hagymasi, A. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26646-5 · Cited by 35
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved
Fritsch, E. F., Burkhardt, U. E., Hacohen, N., & Wu, C. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0526 · Cited by 32
Self-citationAbusarah, J., Khodayarian, F., El-Hachem, N., Salame, N., Olivier, M., Balood, M., Roversi, K., Talbot, S., Bikorimana, J., Chen, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100455 · Cited by 29
Veatch, J. R., Singhi, N., Srivastava, S., Szeto, J. L., Jesernig, B. L., Stull, S. M., Fitzgibbon, M., Sarvothama, M., Yechan-Gunja, S., James, S. E., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144195 · Cited by 28
Impact of anatomic site on antigen-presenting cells in cancer
Zagorulya, M., Duong, E., & Spranger, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001204 · Cited by 27
Veld, R. V. H. I. ‘., Silva, C. G. D., Jager, M. J., Cruz, L. J., & OSSENDORP, F. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091470 · Cited by 26
Lal, J. C., Townsend, M. G., Mehta, A. K., Oliwa, M., Miller, E., Sotayo, A. O., Cheney, E. M., Mittendorf, E. A., Letai, A. G., & Guerriero, J. L. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01448-1 · Cited by 24
Hänel, G., Angerer, C., Petry, K., Lichtenegger, F. S., & Subklewe, M. S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03109-w · Cited by 24
Booty, M. G., Hlavaty, K. A., Stockmann, A. P., Ozay, E. I., Smith, C. K., Tian, L., How, E., Subramanya, D., Venkitaraman, A., Yee, C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100656 · Cited by 24
Fletcher, E. A. K., van Maren, W. W. C., Cordfunke, R. A., Dinkelaar, J., Codée, J. D. C., MAREL, G. V. D., Melief, C. J. M., OSSENDORP, F. A., Drijfhout, J. W., & Mangsbo, S. M. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700911 · Cited by 21
Bochem, J., Zelba, H., Spreuer, J., Amaral, T. M. S., Wagner, N. B., Gaißler, A., Pop, O. T., Thiel, K., Yurttas, C., Soffel, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003439 · Cited by 21
Swartz, A. M., Congdon, K. L., Nair, S. K., Li, Q.-J., Herndon, J. E., Suryadevara, C. M., Riccione, K. A., Archer, G. E., Norberg, P. K., Sanchez-Perez, L. A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-020-00273-5 · Cited by 17
Riccione, K. A., He, L.-Z., Fecci, P. E., Norberg, P. K., Suryadevara, C. M., Swartz, A. M., Healy, P. N., Reap, E. A., Keler, T., Li, Q.-J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1502904 · Cited by 15
STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
Perera, S. A., Kopinja, J. E., Ma, Y., Muise, E. S., Laskey, J., Chakravarthy, K., Chen, Y., Cui, L., Presland, J. P., Sathe, M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0136 · Cited by 14
Hofer, T., Rossi, M., Carboni, S., Berardino-Besson, W. D., von Laer, D., Wollmann, G., Derouazi, M., & Santiago‐Raber, M. (2021) · Cancers · doi:10.3390/cancers13236107 · Cited by 13
Cited by
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
Dynamics and specificities of T cells in cancer immunotherapy
Oliveira, G., & Wu, C. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00560-y · Cited by 525
Self-citationImmune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Robinson, M. H., Villa, N. Y., Jaye, D. L., Nooka, A. K., Duffy, A., McCachren, S. S., Manalo, J., Switchenko, J. M., Barnes, S., Potdar, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167629 · Cited by 48
Metadata
- Authors
- Sellars, M. C., Wu, C. J., & Fritsch, E. F.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 185
- Issue
- 15
- Pages
- 2770-2788
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4285097347
- Cited by
- 318
- References
- 140
- FWCI
- 20.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.